A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: Analysis of sustained interferon γ production in a subset of patients Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Interferon-gamma
  • Interleukin-12
  • Neoplasms
  • Receptor, Epidermal Growth Factor

abstract

  • The addition of IL-12 to trastuzumab therapy did not appear to enhance the efficacy of this antibody treatment. Sustained production of IFN-gamma and other cytokines were observed in three patients: One who exhibited a complete response and two others who had stabilization of disease lasting over 6 months. Given the small sample size and heterogeneity of the patient population, the effects of IL-12 on the innate immune response to trastuzumab therapy should be further explored in the context of a larger clinical trial.

publication date

  • August 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-04-0265

PubMed ID

  • 15297404

Additional Document Info

start page

  • 5027

end page

  • 37

volume

  • 10

number

  • 15